Study: Cancer Patients and Their Families Frustrated with Slow Pace of Drug and Treatment Innovation
COTA announced findings from a study that found 66 percent of cancer patients and their immediate families surveyed think that the speed of clinical trials aimed at driving much-needed innovations in cancer treatments and therapies remains far too slow. The study, which surveyed 1,110 Americans who’ve either had cancer or who’ve had someone in their immediate family with cancer, also found that the recent rapid development of multiple COVID-19 vaccines heightened this belief.
In a recent article published in Forbes, COTA CEO Mike Doyle discussed the devastating impact COVID-19 has had on cancer care.
The pandemic has specifically accelerated the pace of innovation in the realm of real-world data, fueling a number of trends that we expect will carry on and pick up steam post-COVID.
Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.